MorphoSys AG (ETR:MOR) has received an average recommendation of “Hold” from the ten brokerages that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, five have given a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is €95.80 ($111.40).

A number of analysts recently commented on MOR shares. Independent Research set a €120.00 ($139.53) target price on shares of MorphoSys and gave the stock a “neutral” rating in a research note on Tuesday, August 7th. Royal Bank of Canada set a €65.00 ($75.58) target price on shares of MorphoSys and gave the stock a “sell” rating in a research note on Monday, October 1st. Commerzbank set a €107.00 ($124.42) target price on shares of MorphoSys and gave the stock a “neutral” rating in a research note on Wednesday, August 22nd. Oddo Bhf set a €110.00 ($127.91) target price on shares of MorphoSys and gave the stock a “buy” rating in a research note on Thursday. Finally, JPMorgan Chase & Co. set a €100.00 ($116.28) target price on shares of MorphoSys and gave the stock a “buy” rating in a research note on Thursday, August 2nd.

Shares of MorphoSys stock opened at €81.45 ($94.71) on Wednesday. MorphoSys has a 52-week low of €49.63 ($57.71) and a 52-week high of €88.10 ($102.44).

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

See Also: Hedge Funds – How They Work For Investors

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.